Merck & Co.
AWARDS
NEWS
Heidelberg, Germany-based Boehringer Ingelheim has exercised its option to buy an EMBL Ventures portfolio company, ViraTherapeutics. This follows a collaboration and option deal inked between the two companies in August 2016.
Although Hurricane Florence has been downgraded to a Category 2, the massive storm has the potential to dump enough rain to produce catastrophic flooding across the Carolinas. Despite the downgrade, Pfizer is taking no chances and will close its North Carolina injectables plant ahead of the storm.
IRBM signs collaboration agreement with Merck & Co., Inc, Kenilworth, NJ, USA to advance peptide therapeutics
Late-stage trial results show that a combination of Bavencio (avelumab) and Inlyta (axitinib) significantly improved progression-free survival in previously untreated patients with advanced renal cell carcinoma.
Urovant Sciences, a Vivek Ramaswamy company under the Roivant umbrella, has filed for an initial public offering (IPO) to raise $150 million. It will list on Nasdaq under the UROV symbol.
There is a new player in the southern California biotech industry. New venture firm Westlake Village BioPartners launched with a $320 million fund and a leadership well familiar with the ins and outs of the biotech and pharma world.
JOBS
IN THE PRESS